Defy Medical Review: A Peptide Therapy Page That Names No Peptide

"Sermorelin is an FDA-approved secretagogue"

Defy's article "The Benefits of Sermorelin Injections" opens with that sentence.

Checked against FDA's own systems on August 9, 2026, in two places:

Drugs@FDA holds two sermorelin approvals, both for GEREF — NDA019863 and NDA020443, sponsor EMD Serono. Every product record under both applications carries the marketing status Discontinued. ⁴

The openFDA NDC directory returns no finished sermorelin drug product at all. Every listing is a POWDER, marked either "BULK INGREDIENT" or, more often, "BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING" — Letco Medical, Medisca, Darmerica and a dozen overseas API suppliers. ⁵ There is no NDC for a sermorelin product a patient can be dispensed as an approved drug, because no such product is marketed.

Defy's own site says the same thing from the other direction. Its patient-facing article "Medication and Injection Instructions for Sermorelin" states: "Sermorelin Acetate is compounded in the following strength: 15mg (15,000 micrograms)."

A compounded preparation is not FDA-approved. That is definitional, and it is the sentence FDA has spent 2026 writing to telehealth companies about — that compounding pharmacies and their products do not hold approvals, and that saying otherwise misbrands the product. Defy's two pages cannot both be describing the medicine it dispenses.

The benefit argument has the same structure. Two studies are cited: one of "patients who produced little to no hGH" who showed decreased brain function and mood symptoms, and one finding "depressed men release much less hGH during the first three hours of sleep." Neither is a study of sermorelin. The inference runs: low growth hormone accompanies these problems, sermorelin raises growth hormone, therefore sermorelin improves these problems — with the middle step, the trial, missing.

It is missing everywhere. On August 9, 2026, a ClinicalTrials.gov query for AREA[InterventionName]sermorelin returned 11 studies, and not one names sermorelin as its intervention; every record is generic growth-hormone-releasing hormone, tesamorelin, or a GHRH-plus-arginine diagnostic challenge. Broader searches return 27 and 42 studies with the same answer. PubMed returns 19 randomised sermorelin publications, the newest from August 2005, all measuring hormone secretion, growth in children, or a diagnostic response. ⁶ The stronger evidence base belongs to a different GHRH analogue — tesamorelin — and it does not transfer.

Drops under the tongue, dosed in millilitres

Defy publishes an article titled "What are Semaglutide Oral Drops?" It explains that "[t]hese drops are placed under the tongue and absorbed through the salivary glands," and gives a titration schedule: 0.25 mL daily for 30 days, then 0.5 mL daily for 30 days, then 0.75 mL as the final level, with "a dropper in the bottle that measures up to one mL."

The openFDA NDC directory, queried the same day, shows the approved semaglutide dosage forms: an injection solution given subcutaneously, and an oral tablet. Both under NDA. ³ There is no approved sublingual suspension, and nothing approved is dosed in millilitres under the tongue.

So this is a compounded preparation, necessarily. The article never says so. It does not use the word compounded, does not say the preparation is not FDA-approved, and offers no absorption or bioavailability figure for a route the molecule was never developed for — semaglutide's approved oral tablet needs an absorption enhancer and a fasting protocol precisely because peptide absorption across mucosa is the hard part.

What the article does supply is a dosing schedule, which reads as clinical instruction for a product whose delivered dose nobody has measured. It also lists reasons to choose it, and one of them is unusually revealing: "State Regulations — Since injectable Semaglutide is a relatively new medication, state regulations differ on prescribing and shipping it. In those cases, Semaglutide oral drops may be available when other Semaglutide options are not."

That is a formulation being recommended on the grounds that it is available where the studied one is not.

Meanwhile the semaglutide service page carries the evidence, and gets it nearly right. Its headline stat is "14.9% vs. 2.4%" with the note "participants who received Semaglutide lost 14.9% of their overall body weight over a 64 week period." The percentages are exactly STEP 1's: "[t]he mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo." ^{1 2} Four weeks adrift, and the footnote credits an expert-analysis commentary rather than the New England Journal of Medicine paper the numbers are from. Small errors, but this is a page whose whole rhetorical move is that it cites its sources, and the citation points somewhere the number is not.

The 50% that is not in the trial

Defy's female sexual dysfunction page lists Bremelanotide (PT-141) among its treatments and says: "Bremelanotide acts on the central nervous system to improve sexual desire. It has shown as much as a 50% increase in sexually satisfying experiences for women." The FAQ adds "[i]ncreased sexual desire and arousal," "[e]nhanced sensitivity and pleasure," "[i]mproved orgasmic response," and "[w]orks for women who don't respond to other treatments."

Defy deserves credit for naming the molecule at all — many sellers market this as "PT-141" and never print the approved name. But the number has no citation, and the trials it would have to come from say something else.

RECONNECT was two identical phase 3, randomised, double-blind, placebo-controlled trials — NCT02333071 and NCT02338960, 723 and 714 participants, 1,247 in the safety population — testing bremelanotide 1.75 mg subcutaneously as needed for 24 weeks in premenopausal women with hypoactive sexual desire disorder. The published co-primary endpoints are the Female Sexual Function Index desire domain and item 13 of the Female Sexual Distress Scale. The published results: desire increased by 0.30 and 0.42 points in the two studies (integrated 0.35, P<.001), and distress fell by 0.37 and 0.29 points (integrated −0.33, P<.001). ^{7 8 9}

Satisfying sexual events is not among the co-primary endpoints, no 50% figure appears in the published results, and orgasmic response is not what the trials were built to establish. The claim is not a distortion of the trial so much as a different quantity attached to it.

And the omission underneath is the same one as with sermorelin, inverted. Bremelanotide is approved, for exactly the condition Defy's page describes, in exactly the population Defy's page describes. The page never says so. A patient who learned that could ask their physician about the approved product; a patient reading this page learns only that a peptide exists.

A vendor page with no vendors

Defy has a page called "Defy Medical Vendor Information." Its first section is headed Pharmacy. It reads, in full: that these therapies "involve a variety of medications from different pharmacies," that "[u]sing an expansive pharmacy network allows our providers to collaborate with patients on treatment options, offer extended patient choice, and tailor treatments to patients' needs," and that Defy "works to reduce costs for the patient wherever possible."

No pharmacy is named. The Laboratory section names no laboratory — it describes "a laboratory physician cooperative that contracts with accredited national laboratories" — and the Nutritional Supplements section names no manufacturer, only "several supplement manufacturers who produce high quality formulations for clinical use."

A company with no vendor page is merely quiet. A company whose vendor page names no vendor has thought about the question and answered it with a category.

There is one exception, and it is instructive about what Defy is good at. The laboratory section gets genuinely technical where it counts: "Liquid chromatography–mass spectrometry (LC-MS) used to accurately analyze sex hormones, such as Estradiol in males… This methodology is found to be more accurate than other common methods used by other institutions offering hormone therapies." That is a real, checkable methodological claim about how patients are measured, and it is better than most clinics offer. It is also about the blood tests, not the medicines.

The same asymmetry runs through the quality disclosures. The over-the-counter supplement suppliers are described as companies that "voluntarily and certifiably follow cGMP standards for quality control and testing as required by a pharmaceutical manufacturer." The compounded injectables get no sterility standard, no endotoxin limit, no potency tolerance, no USP chapter, no named laboratory and no certificate of analysis. The supplements have a published quality standard. The injections do not.

What is actually here

It is worth being precise about what this review is and is not saying, because Defy is not the kind of operator most of these findings usually attach to.

There is a clinic. 4809 N. Armenia Ave, Suite #220, Tampa, Florida 33603. Tuesday to Friday, 8:00 AM to 5:00 PM Eastern, some Saturdays, walk-ins accepted, telephone 813-445-7342. There is a legal entity, Defy Medical, LLC, with terms governed by Florida law and arbitration in Hillsborough County. There is a named Medical Director, Dr. Justin Saya, on every service page. There is a requirement, written into the patient terms, that out-of-state patients "provide current and updated physical exams every two (2) years." There is no FDA warning letter — the live index returned nothing on August 9, 2026, under a query shape verified by a control that does return one.

Against that: no price anywhere on the site, no regulatory category anywhere on the site, no pharmacy named on the page built to name pharmacies, no testing published for anything injected, no state coverage published while the terms require the patient to guarantee their state is covered, and a flagship product page for a category of medicine that never names a member of the category.

None of that is concealment. Concealment would require the information to be somewhere. It is the disclosure practice of a clinic that is used to explaining these things in a room, working out how to publish a website — and a reader deciding from the website alone is being asked to take the room on trust.